ERBB2 (R896C)

ERBB2 · Variant type: point · HGVS: p.R896C

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Osimertinib	100.0%	0.0%	97.24
2	Mobocertinib	99.9%	0.1%	97.22
3	Neratinib	99.7%	0.3%	93.18
4	Canertinib	99.3%	0.7%	96.49
5	Lapatinib	99.2%	0.8%	99.25
6	Afatinib	98.2%	1.8%	98.50
7	Ibrutinib	97.6%	2.4%	94.74
8	Dacomitinib	97.5%	2.5%	97.99
9	Lazertinib	97.2%	2.8%	97.47
10	Avapritinib	92.7%	7.3%	97.73
11	Brigatinib	91.3%	8.7%	82.96
12	Darovasertib	87.4%	12.6%	96.99
13	Pralsetinib	86.4%	13.6%	93.43
14	Erlotinib	85.4%	14.6%	99.75
15	Gefitinib	82.3%	17.7%	99.25
16	Fostamatinib	81.0%	19.0%	96.74
17	Ponatinib	79.8%	20.2%	78.23
18	Bosutinib	78.5%	21.5%	87.22
19	Zanubrutinib	75.8%	24.3%	98.24
20	Vandetanib	74.3%	25.7%	95.74
21	Dasatinib	56.2%	43.8%	87.97
22	Pirtobrutinib	47.1%	52.9%	99.49
23	Pacritinib	44.3%	55.7%	88.64
24	Defactinib	41.2%	58.8%	92.68
25	Alpelisib	31.0%	69.0%	97.22

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Osimertinib	100.0%	—	—
Mobocertinib	99.9%	—	—
Neratinib	99.7%	—	—
Canertinib	99.3%	—	—
Lapatinib	99.2%	—	—
Afatinib	98.2%	—	—
Ibrutinib	97.6%	—	—
Dacomitinib	97.5%	—	—
Lazertinib	97.2%	—	—
Avapritinib	92.7%	—	—
Brigatinib	91.3%	—	—
Darovasertib	87.4%	—	—
Pralsetinib	86.4%	—	—
Erlotinib	85.4%	—	—
Gefitinib	82.3%	—	—
Fostamatinib	81.0%	—	—
Ponatinib	79.8%	—	—
Bosutinib	78.5%	—	—
Zanubrutinib	75.8%	—	—
Vandetanib	74.3%	—	—
Dasatinib	56.2%	—	—
Pirtobrutinib	47.1%	—	—
Pacritinib	44.3%	—	—
Defactinib	41.2%	—	—
Alpelisib	31.0%	—	—

Cancer	Organ	Source
carcinoma_breast	Breast	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.0ms